ALLOPURINOL; LESINURAD
| Brand name | DUZALLO |
|---|---|
| Active ingredient | ALLOPURINOL; LESINURAD |
| Strength | 300MG;200MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | August 2017 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 8546436 | February 2032 | substance |
| 9956205 | December 2031 | use U-2104 |
| 9216179 | August 2031 | use U-2104 |
| 8357713 | December 2029 | product |
| 8084483 | August 2029 | use U-2104 |
| 8546437 | April 2029 | use U-2104 |
| 8283369 | November 2028 | use U-2104 |
| 10183012 | November 2028 | use U-2104 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.